Enzo Biochem (NYSE:ENZ) Shares Up 8.8%

Enzo Biochem, Inc. (NYSE:ENZ) shares shot up 8.8% during mid-day trading on Tuesday . The company traded as high as $3.10 and last traded at $2.85, 179,114 shares were traded during mid-day trading. An increase of 5% from the average session volume of 169,941 shares. The stock had previously closed at $2.62.

A number of brokerages recently issued reports on ENZ. TheStreet lowered shares of Enzo Biochem from a “c-” rating to a “d+” rating in a research report on Tuesday, November 12th. ValuEngine upgraded shares of Enzo Biochem from a “hold” rating to a “buy” rating in a research report on Saturday, December 7th.

The stock’s 50-day moving average is $2.92 and its 200-day moving average is $3.38. The company has a debt-to-equity ratio of 0.05, a current ratio of 5.09 and a quick ratio of 4.60.

Enzo Biochem (NYSE:ENZ) last announced its earnings results on Tuesday, October 15th. The medical research company reported ($0.11) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.14) by $0.03. The firm had revenue of $20.92 million during the quarter. Enzo Biochem had a net margin of 3.07% and a negative return on equity of 33.03%.

Institutional investors and hedge funds have recently made changes to their positions in the stock. SG Americas Securities LLC boosted its position in shares of Enzo Biochem by 130.9% during the 2nd quarter. SG Americas Securities LLC now owns 30,693 shares of the medical research company’s stock valued at $103,000 after purchasing an additional 17,399 shares in the last quarter. Cutter & CO Brokerage Inc. bought a new position in shares of Enzo Biochem during the 2nd quarter valued at about $63,000. GSA Capital Partners LLP boosted its position in shares of Enzo Biochem by 23.2% during the 2nd quarter. GSA Capital Partners LLP now owns 75,900 shares of the medical research company’s stock valued at $256,000 after purchasing an additional 14,300 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its position in shares of Enzo Biochem by 9.5% during the 2nd quarter. Charles Schwab Investment Management Inc. now owns 254,331 shares of the medical research company’s stock valued at $858,000 after purchasing an additional 22,156 shares in the last quarter. Finally, Bank of New York Mellon Corp boosted its position in shares of Enzo Biochem by 11.3% during the 2nd quarter. Bank of New York Mellon Corp now owns 249,095 shares of the medical research company’s stock valued at $839,000 after purchasing an additional 25,203 shares in the last quarter. Hedge funds and other institutional investors own 68.60% of the company’s stock.

Enzo Biochem Company Profile (NYSE:ENZ)

Enzo Biochem, Inc, an integrated diagnostic bioscience company, researches, develops, manufactures, and markets diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. It operates in three segments: Life Sciences Products, Clinical Laboratory Services, and Therapeutics.

Featured Story: Stochastic Momentum Index (SMI)

Receive News & Ratings for Enzo Biochem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzo Biochem and related companies with MarketBeat.com's FREE daily email newsletter.